DiaMedica Therapeutics Inc.

Good morning, ladies and gentlemen, and welcome to the Diametica Therapeutics First Quarter 2025 Conference Call. An audio recording of the webcast will be available shortly after the call today on Diametica's website at .diametica.com in the Investor Relations section. Before Diametica proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results, appears in the section entitled, Cautionary Note Regarding Forward-Looking Statements, in the company's press release issued yesterday and under the heading, Risk in the Company's Most Recent Annual Report on Form 10-K and Most Recent Quarterly Report Form 10-Q. Diametica's SEC filings are available on the SEC's website, .sec.gov, and on its website, diametica.com. Please also note that any comments made on today's call speak only as of today, May 14, 2025, and may no longer be accurate at the time of any replay or transcript rereading. Diametica disclaims any duty to update its forward-looking statements. Following the prepared remarks, the phone lines will be open for questions. I would now like to turn you over to your host for today's call, Mr. Rick Pauls, Diametica's President and Chief Executive Officer. Mr.

Pauls? Thank you, Operator. Hello everyone, and welcome to our first quarter 2025 conference call. I am joined this morning by Scott Kellan, our Chief Financial Officer. Dr. Lorianne Masioka is currently on short-term medical leave, and we hope she gets well soon. We're happy to be here today to update you on the progress on our two clinical development programs. It has only been a short interval since our last update, thus I will keep my remarks brief. That said, I'm pleased to report that we continue to make substantial progress in both of our clinical development programs. I'll start with an update on our Precampsia program. Building upon the significant accomplishments of this program within a very short timeframe, as we discussed in March, we're pleased to be able to disclose that we believe Part 1A of our Phase 2 investigator-sponsored Precampsia trial is very close to identifying a target dose to move forward within in Part 1B. Dose selection will be guided primarily by a few key data points, which we expect to be sharing in our upcoming preliminary topline results from the Part 1A proof of concept portion of the trial. These key data points include, one, safety and tolerability, including results of a percentile transfer analysis, two, the amount of decrease in systolic and diastolic blood pressure levels, and three, changes in uterine and placental blood flow as assessed by the Doppler ultrasound measurement of the uterine artery pulsatility index. This measure is important as reductions in the pulsatility index may suggest decreased downstream resistance and improved uterine and placental blood flow, which could also be an indication of disease modifying. Currently, we expect to be in a position to release those preliminary topline results between the second half of June and the first half of July. The final timing will be primarily dependent on the schedules at the outside laboratories running the various tests, including the pharmacodynamic biomarkers and the assay, which will be used to determine if DM1A9 crosses the placental barrier. One additional update, May is Precampsia Awareness Month, and we will be sponsoring a Precampsia Awareness Month, a key opinion leader call on May 28th at 8 a.m. Eastern. Compared to other therapeutic areas like oncology, which have advanced more rapidly in recent years, the treatment of pregnancy complications remains outdated and is not well understood. No FDA-approved treatments exist for Precampsia, despite the growing burden of this disease. To our knowledge, DM1A9 is the only novel agent currently being studied in pregnant women with Precampsia. With this KOL event, we will continue our work to educate investors, physicians, and other interested parties on Precampsia as a disease and the current state of treatment. With this background, we will also discuss the design of our current phase two trial of DM1A9 in Precampsia. Turning briefly to our stroke program, enrollment is moving ahead steadily, and we're pleased to announce that participant enrollment now is between the 20th and 25th percentile mark of patients enrolled for the interim analysis. Our next enrollment update will be at the 50th percentile mark. We believe that our efforts over the past year to engage with sites, to promote communications between the sites, and to simplify study logistics have been important in driving the recent uptick in enrollment. Accordingly, we reiterated our guidance that the interim analysis on those first 200 participants will be completed in the first half of 2026. We'd also note for you that we have engaged an experienced stroke neurologist to support site engagement during Laurieann's leave in order to maintain our enrollment momentum in the Remedy 2 trial. This individual has spent over 10 years treating stroke patients at a major US research center and also has five years of recent biotech drug development experience. He has been doing a tremendous job connecting with and maintaining our relationships with sites and supporting our recent enrollment momentum. Now I'd like to hand the call over to Scott Kellan to review this quarter's financial results.

Thanks, Rick, and good morning, everyone. As the operator mentioned, we announced our first quarter 2025 financial results and filed our quarterly report on Form 10Q yesterday after the markets closed. These documents are both available on either the DIAmedica or the SEC websites. As of March 31, 2025, we reported a total combined cash and investments of $37.3 million, current liabilities of $4.7 million, and working capital of $32.8 million. This compares to a total combined cash and investments of $44.1 million, $5.4 million in current liabilities, and $39.2 million in working capital as of December 31, 2024. The decreases in combined cash and investments and in working capital were due primarily to the net cash used to fund our operations. The net cash used in operating activities for the first quarter of 2025 was $7.1 million compared to $6.7 million for the first quarter of 2024. The increase in cash used in operating activities resulted primarily from our increased net loss, partially offset by changes in operating assets liabilities occurring during the current year period. We anticipate that our current cash and investments provides us a runway into Q3 of 2026. Our research and development expenses increased to $5.7 million for the three months ended March 31, 2025, up from $3.7 million for the three months ended March 31, 2024. The increase was due primarily to cost increases resulting from the continuation of our Remedy II clinical trial, including our global expansion, increased manufacturing development activity, and the expansion of our clinical team during 2024. These increases were partially offset by cost reductions related to in-use study work performed and completed in the prior year period. We expect that our R&D expenses will moderately increase in future periods relative to our recent prior periods as we continue our Remedy II trial, including the global expansion and our continued expansion of our DM 199 clinical development program in preeclampsia. Our general and administrative expenses were $2.5 million and $2.1 million for the three months ended March 31, 2025, and 2024 respectively. This increase resulted primarily from additional non-cash share-based compensation expense recognized as the result of the approval of an extension of the post-termination exercise period for stock options held by a retiring member of our board of directors. We expect G&A expenses to remain steady in future periods as compared to recent prior periods. Our net other income was $443,000 for the three months ended March 31, 2025, compared to $597,000 for the three months ended March 31, 2024. This decrease was driven by reduced interest income recognized during the current year period related to lower average marketable securities balances during the current year period as compared to the prior year period. With that, let me ask the operator to open the lines for questions.

Thank you so much. Ladies and gentlemen, we will now begin our question and answer session. Should you have a question, please press star followed by 1 on your touchtone phone. You will hear a prompt that your hand has been raised. Should you wish to remove your hand from the queue, please press star followed by 2. If you're using a speakerphone, please lift the handset before

pressing any keys. One moment for your first question. Your first question comes from Thomas Flatten with Lake Street. Please go ahead.

Good morning. I appreciate you taking the questions. Hey, Rick, just to clarify, the laboratory test results that seem to be the variable in terms of the readout between June and July, is that primarily the test for DM 199 crossing the placental barrier in the umbilical cord? Is there something else there that we should be aware of?

Yeah, Thomas. Yeah, absolutely. So, that's the main item is going to be the placental transfer. So, we have an assay that we're just having finalized in terms of getting to lower limits of detection. And so, it's just a question of time for them to run it. So, we want to at least give a range today in terms of when we anticipate the results.

Makes sense. And then, I see you mentioned that you're expecting to start Part 1B in Q3. What are the triggers for Part 2 and 3, so the expected management and the fetal growth restriction components of the study?

So, I'll start off with the fetal growth restriction. So, if we see dilation of the intrauterine arteries, our investigators are prepared to move ahead with that cohort. And then, we'll have more to talk about the Part 2 when we daylight the results here in the coming weeks.

Excellent. I appreciate you taking the questions. Thank you. Thanks, Thomas.

Your next question comes from Matthew Caulfield with HC Wainwright. Please go ahead.

Hi, good morning, guys. Thanks for taking our question. I was wondering if you could speak to the anticipated read-through or any de-risking between the initial preeclampsia data and how that profile could translate to AIS development and the Remedy 2 trial. Thanks again.

Sure. I mean, I'll start off by saying that these are definitely two very unique indications. But I will add that a positive effect here in preeclampsia will just be another confirmation that this protein is active. And I would also mention around that we've previously talked about the fact that there are two forms of this protein in Asia that are being used. So, the form of the protein isolated from human urine that today is treating close to a million patients per year for acute ischemic stroke. And then there's also a form of the protein isolated from pig pancreas in both Japan and China. And we've been able to track down about 10 publications with that form of the protein to treat preeclampsia. So, I think it will just be very encouraged that we have an active protein. And what we're seeing in some of the validation and rationale for going into both of these indications is what we'll call the crude forms in Asia today.

Thanks a lot. Appreciate you guys. Thank you.

Your next question comes from Chase Nickerbacher with Craig Hallam.

Please go ahead.

Good morning. Thanks for taking the questions. Rick, just on stroke, be good to kind of get some incremental details on enrollment. I mean, maybe just kind of starting out with those high volume or potential high volume centers. You know, can you kind of give us an update on what percentage of kind of those high volume accounts are now, you know, at that one to two per month that you want to see?

I would add that, you know, as we had kind of talked on past calls, we really did think that there would be a small number of sites, in particular in the US, that would drive enrollment. And, you know, as we're starting to build some momentum, that's clearly what we're starting to see. So some of these high enrolling sites are seeing the one to two patients per site per month. And so we're working on building momentum and then really working hard on some of those other sites to expand the relationship here to encourage. But, you know, I say currently we are above our plan here now and, you know, we're encouraged with momentum that's being built.

So maybe just an update on overall centers as well as, you know, again, it's only been a couple of months here. But, you know, have we have we expanded that past 30? Maybe on the geographic footprint of those centers that we started to see some international enrollment come in.

Yeah, so we're currently in mid thirties and keeping in mind that there are sites now that are not performing that we're shutting down. And so we're really again focusing on the high enrolling sites. We also have sites in Georgia that have been been performing very well. And that's where that is the country of Georgia.

Yeah, yeah, I got it. And just kind of, I guess, summing all this up, you know, first half 26 interim analysis, I think at least implies that, you know, enrollment rates continue to pick up. And I mean, you're seeing that trajectory in recent weeks, recent months, as far as that that curve continuing to steepen.

Yeah, absolutely. And from the last earnings call, you know, we're definitely seeing

an encouraging uptick. Got it. That's it for me. Thanks. Great. Thanks, Jason.

Our next question comes from Thomas Flatten with Lake Street. Please go ahead.

Yeah, hey, thanks for taking the taking another question. Just back to preeclampsia real quick. The part two and three, those are those studies will be primarily based out of South Africa, or are you thinking that there's going to be a U.S. component to those which would necessitate NIND filing?

So that part, parts two and part three are still part of the same protocol. And so our collaborators will not need to go back for regulatory clearance.

And at some point, will you expand the study? And if so, when into the U.S.?

We do plan in the future to expand this to the U.S. and global. And we'll have we'll have more to share at a later date. Right now, again, the focus is you're getting the part one A and then moving into part one B as well as part two and then three, hopefully. Got it. Appreciate it.

Thank

you.

Thanks,

Thomas.

Thank you. There are no further questions at this time. I would like to turn the call back to Mr. Rick Pulse.

All right. In closing, we're very encouraged by our steady progress and clear momentum across both the preeclampsia and stroke programs. We look forward to sharing upcoming key milestones, including the top line results from our preeclampsia proof of concept trial and the interim analysis from our stroke program. We thank our dedicated team, investigators and importantly, our patients and their families for the continued trust and commitment. Please also mark your calendars from May 28th at 8 a.m. Eastern time for our preeclampsia KOL event. We'll be sending out call in details via press release early next week. As always, we appreciate the ongoing support of our shareholders and look forward to updating you further in the months ahead. Thank you again for joining our call today. This concludes our call.

Ladies and gentlemen, you may now disconnect.